IRAK4 and myelodysplastic syndrome: Our data suggests that inhibiting IRAK4 pharmacologically leads to shrinkage of the MDS/AML clones in vivo and this correlates with decreased blast counts seen with CA4948 monotherapy in relapsed/refractory MDS/AML in early results.